Supplemental Table 1: Baseline HPV antibody titers and subsequent risk of corresponding oral HPV infection for HPV types 16, 33, and 45.

Measure*	Oral HPV incidence					
	N	Oral HPV Infections	Person-time (person-years)	Incidence Rate (infs/100 p-ys)	Unadjusted HR	Adjusted HR^
HPV 16 L1 seropositive						
No	606	16	1459	1.10	REF	REF
Yes- Tertile 1 (.2-.29)	61	3	141	2.13	1.8 (0.55-5.8)	1.5 (0.36-6.6)
Yes- Tertile 2 (.29-.46)	61	3	146	2.05	1.7 (0.53-5.6)	1.3 (0.37-4.8)
Yes- Tertile 3 (>.46)	61	1	140	0.71	0.63 (0.08-4.8)	0.44 (0.05-3.7)
HPV 33 L1 seropositive						
No	510	10	1286	0.78	REF	REF
Yes- Tertile 1 (.12-.18)	93	0	232	0	---	---
Yes- Tertile 2 (.19-.31)	93	1	252	0.40	0.52 (0.07-4.0)	0.37 (0.05-2.6)
Yes- Tertile 3 (>.31)	93	0	223	0	---	---
HPV 45 L1 seropositive						
No	558	8	1422	0.56	REF	REF
Yes- Tertile 1 (.28-.37)	77	3	192	1.56	2.7 (0.72-10.2)	3.2 (0.76-13.7)
Yes- Tertile 2 (.37-.55)	77	5	197	2.54	4.5 (1.5-13.9)	5.8 (1.2-28.5)
Yes- Tertile 3(>.55)	78	3	189	1.59	2.9 (0.75-10.8)	2.5 (0.35-17.0)

^Adjusted for age, gender, smoking status, number of recent and lifetime oral sex partners, HIV/CD4 status, study site, and frequency of recent toothbrushing

*Seropositivity measured via the ELISAs optical density values